Ceregene is a biotechnology company focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders using a proprietary gene delivery technology. It offers gene therapy products for Alzheimer’s disease and Parkinson’s disease. The company also has research programs investigating therapies for other neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), ocular diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and glaucoma, and Huntington’s disease.